FDA grants Akesis an IND application for Type 2 diabetes drug trial
The FDA has accepted Akesis Pharmaceuticals’ investigational new drug (IND) application for AKP-020, a vanadium compound, to test its safety and efficacy in patients with Type 2 Diabetes.
The Austin, Texas-based medical research organization, dgd Research, has begun screening patients for the Akesis’ Phase IIa trial. The study is a controlled U.S. clinical trial measuring efficacy (using the gold-standard euglycemic-hyperinsulinemic clamping procedure), as well as pharmacokinetic parameters, safety and tolerability of AKP-020 in diabetic patients.
The San Diego based Akesis said its AKP-020 is the product designation for a novel vanadium compound, known as bis(ethylmaltolato)oxovanadium (IV), or BEOV. The compound was invented and developed by University of British Columbia researchers and is licensed exclusively to Akesis Pharmaceuticals, the company said.
The Austin, Texas-based medical research organization, dgd Research, has begun screening patients for the Akesis’ Phase IIa trial. The study is a controlled U.S. clinical trial measuring efficacy (using the gold-standard euglycemic-hyperinsulinemic clamping procedure), as well as pharmacokinetic parameters, safety and tolerability of AKP-020 in diabetic patients.
The San Diego based Akesis said its AKP-020 is the product designation for a novel vanadium compound, known as bis(ethylmaltolato)oxovanadium (IV), or BEOV. The compound was invented and developed by University of British Columbia researchers and is licensed exclusively to Akesis Pharmaceuticals, the company said.